Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPAɣ8 Receptor Occupancy of JNJ-64140284
NCT03693391Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-64140284 in epilepsy (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Total and Regional Brain Compartmental Kinetics for Volume of Distribution (V[t]) of 18FJNJ-64511070 at Day 2 and Percentage of Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA gamma 8) Receptor Occupancy at Day 2. Started Oct 2018; status: terminated.
02
Drugs
JNJ-64140284
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03693391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693391.